Anticancer prodrugs have attracted significant attention from the medical and scientific communities in recent years because of their potential to improve treatment precision while reducing side effects. These drugs are engineered to remain inactive until they are activated at specific sites or under particular physiological conditions within the body, at which point they release their therapeutic effect.